Under an agreement, ProBioGen will develop a stable cell-line for and manufacture an anti-cancer antibody for Chiome using its proprietary cancer cell-killing technology.
ProBioGen, a service and technology provider for complex therapeutic glycoproteins, announced on Oct. 5, 2017 that it signed a service and license agreement with Chiome Bioscience, a Japanese antibody discovery and development company, to use ProBioGen’s cancer cell-killing technology, GlymaxX, for a clinical candidate in an antibody manufacturing program for Chiome.
Specifically, ProBioGen will develop a stable GlymaxX cell line and then will conduct process development and GMP manufacturing of the antibody, which is derived from antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced cancer stem cells. The antibody will be optimized for cancer cell-killing activity.
Dr. Koji Nakamura, head of drug discovery laboratories and former CEO of LivTech, an R&D and antibody drug discovery company acquired by Chiome in December 2013, explained in a company press release: “We have tested ProBioGen’s GlymaxX technology for our antibody before and saw in-vivo in animal models an obviously potentiated cancer cell-killing efficacy of its afucosylated version. This, together with our long-standing relationship with the ProBioGen team, the company’s demonstrated track record in developing stable cell lines up to reliable GMP manufacturing for small and big biotechs, and the favorable, royalty-free commercial GlymaxX Terms, made our selection quite simple.”
“We look much forward to a productive partnership which combines Chiome’s outstanding antibody drug candidate, LIV-1205, with our own antibody development expertise and our GlymaxX ADCC enhancement technology to make together with Chiome a marked contribution to combat various cancers,” said ProBioGen’s CEO Wieland Wolf in the release.
Source: ProBioGen
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.